(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree- Vote In favor of Your #1 sort of film
- Audits of the Top Science fiction Movies This Year
- Polish law aimed at lowering petrol prices takes effect on Tuesday
- Doctors looking into hormone therapy as a way to ward off dementia in women
- Top 15 Supportable Design Brands Coming out on top
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- Email Promoting Instruments for Compelling Efforts
- Five killed in Israeli air strikes on tents near Khan Younis, medics say
